Aitia
Open siteIntroduction
Discover breakthrough drugs with Aitia.
Aitia Product Information
Aitia: Discovering the next generation of drugs with Gemini Digital Twins
Aitia is an AI-enabled biotech company committed to accelerating the discovery and development of life-saving therapeutics. By revealing the hidden biological mechanisms of disease through causal AI, multi-omic patient data, and Gemini Digital Twins, Aitia aims to shorten timelines and improve success rates in bringing breakthrough drugs to patients in need.
Our Science
- Mission: Build the leading AI-enabled biotech company that speeds up drug discovery and development to meaningfully impact patients’ lives.
- Core approach: Use causal AI, multi-omic patient data, and Gemini Digital Twins to model human disease mechanisms and identify therapeutic strategies.
- AI-driven pipeline: Develop first-in-kind programs that leverage digital twins to explore disease biology and drug responses in oncology and neurodegenerative diseases.
How It Works
- Causal AI and multi-omics: Integrate diverse patient data (genomics, transcriptomics, proteomics, etc.) to uncover causal drivers of disease.
- Gemini Digital Twins: Create digital representations of human disease states informed by real patient data to simulate disease progression and drug responses.
- AI-enabled discovery: Use advanced AI to identify novel targets, design therapeutics, and predict clinical outcomes from digital twin simulations.
The combination of causal modeling, rich multi-omic data, and Gemini Twins aims to reveal actionable biology and accelerate therapeutic discovery with a data-driven, hypothesis-led pipeline.
Our AI Approaches
- AI-driven drug discovery and target identification leveraging causal inference.
- Digital twin technology to simulate patient-specific disease trajectories and drug effects.
- Integration of multi-omic data to capture complex biology and heterogeneity across patient populations.
- Partnerships to apply AI capabilities in real-world therapeutic development timelines.
Pipeline and Programs
- Aitia’s pipeline consists of differentiated, novel programs in oncology and neurodegenerative diseases.
- Each program uses Gemini Digital Twins to explore mechanism-based hypotheses and accelerate preclinical and translational work.
- Focus areas include first-in-kind approaches designed to address rapid, devastating impacts on patients and families.
The Team
Aitia brings together AI pioneers, R&D veterans, and biotech builders. The team is backed by top-tier healthcare and strategic pharma leaders, collaborating to translate AI breakthroughs into meaningful patient outcomes.
Partnerships and Collaboration
- Strategic partnerships in AI-enabled drug discovery to lead the way in breakthrough therapeutics.
- Collaborations with industry leaders across diverse therapeutic areas to accelerate discovery and development.
Careers: Join Us
Join the future of biotech and help shape tomorrow's discoveries. Explore opportunities to contribute to AI-enabled drug discovery, multi-omic data science, and Gemini Digital Twin development.
Latest News
- Aitia expands collaboration with Servier to discover and develop new drugs for brain cancer using AI-driven digital twins.
- Industry events and thought leadership on the state of AI in drug discovery.
Contact
561 Windsor St, Somerville, MA 02143 | Phone: 617.374.2300
Core Features
- AI-powered drug discovery using causal AI and multi-omic data integration
- Gemini Digital Twins to model human disease and predict drug responses
- Differentiated, first-in-kind oncology and neurodegenerative programs
- AI-enabled pipeline with rapid hypothesis testing and translational focus
- Partnerships with industry leaders to accelerate development
- Team of AI pioneers, R&D veterans, and biotech builders
- Strategic collaborations across therapeutic areas
- Privacy-conscious data handling and secure data integrations